595 related articles for article (PubMed ID: 37479526)
1. Efficacy of quadruple therapy with clarithromycin based on faecal molecular antimicrobial susceptibility tests as first-line treatment for
Wu Y; Wang Y; Liu X; Liao O; Lou G; Li Y; Wu H; Du Q; Ye J
BMJ Open; 2023 Jul; 13(7):e072670. PubMed ID: 37479526
[TBL] [Abstract][Full Text] [Related]
2. Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China.
Xie Y; Zhu Z; Wang J; Zhang L; Zhang Z; Lu H; Zeng Z; Chen S; Liu D; Lv N;
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914954
[TBL] [Abstract][Full Text] [Related]
3. Rabeprazole plus amoxicillin dual therapy is equally effective to bismuth-containing quadruple therapy for Helicobacter pylori eradication in central China: A single-center, prospective, open-label, randomized-controlled trial.
Shao QQ; Yu XC; Yu M; Ma J; Zhao JB; Yuan L; Qi YB; Hu RB; Wei PR; Xiao W; Lan L; Jia BL; Zhang LZ; Ding SZ
Helicobacter; 2022 Apr; 27(2):e12876. PubMed ID: 35150597
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of quadruple regimen with polaprezinc for gastric
Wu D; Sun Z; Li T; Tan Q; Sun Y; Chen T; Liu Y; Li J; Jiang H; Yuan Z; Zhao Y; Chen W
BMJ Open; 2020 Nov; 10(11):e037182. PubMed ID: 33203625
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial.
Chen S; Shen W; Liu Y; Dong Q; Shi Y
Chin Med J (Engl); 2023 Jul; 136(14):1690-1698. PubMed ID: 37469024
[TBL] [Abstract][Full Text] [Related]
6. Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for
Bang CS; Lim H; Jeong HM; Shin WG; Choi JH; Soh JS; Kang HS; Yang YJ; Hong JT; Shin SP; Suk KT; Lee JJ; Baik GH; Kim DJ
Gut Microbes; 2020 Sep; 11(5):1314-1323. PubMed ID: 32362221
[TBL] [Abstract][Full Text] [Related]
7. Bismuth-containing quadruple therapy versus concomitant quadruple therapy as first-line treatment for Helicobacter Pylori infection in an area of high resistance to clarithromycin: A prospective, cross-sectional, comparative, open trial.
Macías-García F; Bastón-Rey I; de la Iglesia-García D; Calviño-Suárez C; Nieto-García L; Domínguez-Muñoz JE
Helicobacter; 2019 Feb; 24(1):e12546. PubMed ID: 30346636
[TBL] [Abstract][Full Text] [Related]
8. Comparison of 10 and 14 days of antofloxacin-based versus 14 days of clarithromycin-based bismuth quadruple therapy for Helicobacter pylori eradication: A randomized trial.
He XJ; Wang XL; Huang XY; Li DZ; Liu G; Wang W; Li DL
Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102052. PubMed ID: 36400418
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of furazolidone- and amoxicillin-based quadruple therapy for
Zhang YW; Hu WL; Cai Y; Zheng WF; Du Q; Kim JJ; Kao JY; Dai N; Si JM
World J Gastroenterol; 2018 Oct; 24(40):4596-4605. PubMed ID: 30386109
[TBL] [Abstract][Full Text] [Related]
10. Clarithromycin versus furazolidone for naïve Helicobacter pylori infected patients in a high clarithromycin resistance area.
Qiao C; Li Y; Liu J; Ji C; Qu J; Hu J; Ji R; Wan M; Lin B; Lin M; Qi Q; Zuo X; Li Y
J Gastroenterol Hepatol; 2021 Sep; 36(9):2383-2388. PubMed ID: 33691344
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of bismuth-based quadruple therapy for eradication of Helicobacter pylori infection based on previous antibiotic exposure: A large-scale prospective, single-center clinical trial in China.
Zhou JJ; Shi X; Zheng SP; Tang D; Cai T; Yao Y; Wang F
Helicobacter; 2020 Dec; 25(6):e12755. PubMed ID: 32914914
[TBL] [Abstract][Full Text] [Related]
12. Furazolidone, amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of Helicobacter pylori.
Cheng H; Hu FL
World J Gastroenterol; 2009 Feb; 15(7):860-4. PubMed ID: 19230048
[TBL] [Abstract][Full Text] [Related]
13. Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.
Liou JM; Jiang XT; Chen CC; Luo JC; Bair MJ; Chen PY; Chou CK; Fang YJ; Chen MJ; Chen CC; Lee JY; Yang TH; Yu CC; Kuo CC; Chiu MC; Chen CY; Shun CT; Hu WH; Tsai MH; Hsu YC; Tseng CH; Chang CY; Lin JT; El-Omar EM; Wu MS;
Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):228-241. PubMed ID: 36549320
[TBL] [Abstract][Full Text] [Related]
14. Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial.
Kim YI; Lee JY; Kim CG; Park B; Park JY; Choi IJ
BMC Gastroenterol; 2021 Mar; 21(1):95. PubMed ID: 33653284
[TBL] [Abstract][Full Text] [Related]
15. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.
Tsay FW; Wu DC; Yu HC; Kao SS; Lin KH; Cheng JS; Wang HM; Chen WC; Sun WC; Tsai KW; Hsu PI
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807915
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility-guided sequential strategy versus empirical therapy for Helicobacter pylori infection: study protocol for a randomised controlled trial.
Lu K; Lang C; Zou X; Zang L; Sang W; Feng Q; Mu Y; Liu L; Xu C; Zhao J
Trials; 2023 Jun; 24(1):413. PubMed ID: 37337241
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of triple therapy containing berberine hydrochloride, amoxicillin, and rabeprazole in the eradication of Helicobacter pylori.
Chen XX; Chen YX; Bi HX; Zhao X; Zhang LF; Liu JY; Shi YQ
J Dig Dis; 2022 Oct; 23(10):568-576. PubMed ID: 36415112
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of real-time PCR-based detection of Helicobacter pylori infection and genotypic resistance-guided quadruple therapy as the first-line treatment for functional dyspepsia with Helicobacter pylori infection.
Liu Q; Qi D; Kang J; Jin Y; Liu W; Gao W; Hou P; Lu J
Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):221-5. PubMed ID: 25629566
[TBL] [Abstract][Full Text] [Related]
19. Bismuth, rabeprazole, amoxicillin, and doxycycline as first-line Helicobacter pylori therapy in clinical practice: A pilot study.
Gu L; Li S; He Y; Chen Y; Jiang Y; Peng Y; Liu X; Yang H
Helicobacter; 2019 Aug; 24(4):e12594. PubMed ID: 31119830
[TBL] [Abstract][Full Text] [Related]
20. Half-dose clarithromycin-containing bismuth quadruple therapy is effective and economical in treating Helicobacter pylori infection: A single-center, open-label, randomized trial.
Lu B; Wang J; Li J; Liu L; Chen Y
Helicobacter; 2019 Apr; 24(2):e12566. PubMed ID: 30780194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]